The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|January 30, 2019
Lonza Names New CEO
Author(s)Pharmaceutical Technology Editors
CDMO leader Marc Funk will succeed Ridinger as CEO of Lonza.
Advertisement
Lonza announced on Jan. 30, 2019 that Richard Ridinger, CEO, will retire from the company after seven years; Marc Funk, currently chief operating officer of the Pharma & Biotech division will succeed Ridinger as CEO effective March 2, 2019. Ridinger will remain with the company until the end of April and will be available in an advisory capacity until the end of 2019.
“Richard’s achievement at Lonza's main site in Visp (CH) deserves special mention. He took over a site with uncertain prospects and developed it into a pioneering industrial performance center. I look forward to working with him and Marc to ensure a seamless transition of leadership and wish Richard all the best for the future,” said Albert M. Baehny, chairman of Lonza’s board of directors in a statement announcing the change.
“I congratulate Marc Funk on his appointment. Since 2014, he has led Lonza’s fastest-growing division and built it to become the CDMO partner of choice for pharma and biologics companies. This experience has prepared him very well for his new role as chief executive officer,” the Chairman said. “The Board is delighted to have a strong internal successor to lead the company in the exciting years ahead.”
“Lonza has only been able to achieve its strategic, operational, and financial objectives through the close cooperation of all stakeholders. I would like to express my personal appreciation to all the colleagues, customers, and partners around the world for their valued contributions to Lonza’s success,” said Ridinger in the statement.
Source:
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Advertisement
Advertisement